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18 In embyos and anlae, we observed no stanng w~t h AbH3 probably because of nsuffcent S F expres- form of T F has been constructed that contains only the cell surface domain (4) .This truncated T F (tTF) is a soluble protein with a factor X-activating activity that is about five orders of magnitude less than that of native transmembrane TF in an appropriate phospholipid membrane environment (5). This is because the TF:VIIa complex binds and activates factors IX and X far more efficiently when associated with a negatively charged phospholipid surface (5, 6). We reasoned that, by using an antibody to target tTF to tumor vascular endothelium, the tTF would be brought into proximity with a cell surface so as to recover in part its native function and locally initiate thrombosis. Such an antibody-tTF conjugate (or "coaguligand") would selectively thrombose tumor vasculature.
T o test this concept, we used a mouse model 111 which the tumor vascular endothelium expresses a marker that is lacking on the normal vascular endotheli~ltn(7). Nat~lrallyoccurring markers of tumor vascular endothelium have not been identified in mice, although some strong candidates have been identified for humans (see below). In our model, C1300 ( arm of the lOHlO antibody, specific for a noninhibitory epitope on the C-module of tTF (8) . This bispecific antibody, B21-21 10H10, mediated the binding of tTF in an antigen-specific manner to I-Ad on A20 mouse B-lymphoma cells in vitro (Fig. 1A) . When mouse plasma was added to A20 cells to which tTF had been bound by B21-21 10H10, it coagulated rapidly. Fibrin strands were visible 36 s after the addition of plasma to antibody-treated cells, as compared with 164 s when plasma was added to untreated cells (Fig. 1B) . This enhanced coagulation was observed only when tTF was bound to the cells; no effect on coagulation time was seen with cells incubated with tTF alone, with homodimeric F(ab')2, with Fab' fragments, or with tTF plus bispecific antibodies that had only one of the two specificities needed for binding tTF to A20 cells.
There was a linear relation between the logarithm of the number of tTF molecules bound to the cells and the rate of plasma coagulation by the cells (Fig. 1C) . In the presence of cells alone, plasma coagulated in 190 s, whereas at 300,000 molecules of tTF per cell, the coagulation time was 40 s. Even with only 20,000 molecules per cell, coagulation was faster (140 s) than with untreated cells. These in vitro experiments showed that the thrombogenic potency of tTF is enhanced by cell surface proximity mediated through antibody-directed binding to class I1 antigens on the cell surface.
A histological study was performed to determine whether intravenous administration of the B21-2/10HlO*tTF coaguligand induced selective thrombosis of tumor vasculature in mice bearing subcutaneous C1300(Muy) neuroblastomas 0.8 to 1.0 cm in diameter (9) (Fig. 2) . Within 30 min, all vessels throughout the tumor were thrombosed, containing occlusive platelet aggregates, packed erythrocytes, and fibrin. At this time, tumor cells were histologically indistinguishable from tumor cells of untreated mice. After 4 hours, however, there were signs of tumor cell injury. The majority of tumor cells had separated from one another and had pyknotic nuclei, and the tumor interstitium commonly contained erythrocytes. By 24 hours, the tumor showed advanced necrosis, and by 72 hours, the entire central region of the tumor had condensed into amorphous debris. In contrast, there was no visible thrombosis of tumor vessels in mice 30 min after injection with equivalent quantities of tTF alone or tTF in combination with control bispecific antibodies (OX7/10H10, CAMPATH-21 10H10, or B21-210x7) that had only one of the two specificities needed for binding of tTF to I-Ad. Similarly, no thromboses were found in nontransfected C1300 tumors, where the, endothelium lacks I-Ad.
These experiments indicated that the predominant occlusive effect of the B2 1-21 10HlO.tTF coaguligand on tumor vessels is mediated through binding to class I1 antigens on tumor vascular endothelium. Nevertheless, a nonspecific thrombotic action of tTF was discernible in tumor vessels at later times; in tumors from mice that had been injected 24 hours previously with tTF alone or tTF mixed with the control bispecific antibody OX7/10H10, an average of 40% and 60% of the vessels were thrombosed, respectively. These were most prevalent in the tumor core. It is possible that the resident thrombogenic activity of tumor vasculature (10) renders these vessels more susceptible to thrombosis even by untargeted tTF. Alternatively, enhanced procoagulant changes might have been induced by the tumor-derived IFN-y. Coaguligand treatment was well tolerated (I 1 ); mice lost no weight and retained a normal appearance and level of activity. Neither thrombi nor histological abnormalities were found in the liver, kidney, lung, intestine, heart, brain, adrenals, pancreas, or spleen from the tumor-bearing mice 30 min or 24 hours after administration of coaguligand or free tTF.
We next investigated whether intravenous administration of the B21-2/ 10H10-tTF coaguligand could inhibit the growth of large tumors (diameter 0.8 to 1.0 cm) in mice (9) . The pooled results from three separate experiments (Table 1 and The antitumor effect of the B21-2/ 10HlO.tTF coaguligand was attributable in part to a nontargeted effect of tTF. Tumors Table 1 . Antitumor effects of 821 -2/1 OH1 0-tTF coaguligand. The tumor growth index is the ratio of mean tumor volume on day 14 to mean tumor volume on day 0. CR, complete regression; PR, partial remission (>50% decrease in initial tumor volume); NR, no response (~5 0 % decrease in initial tumor volume). Two-tailed Pvalues are for differences in tumor volume (day 14) by the Mann-Whitney rank sum test; NS, not significant. The nontargeted effect of tTF on tumor growth presumably derives from its slight residual thrombogenic activity coupled with the endogenous thrombogenic activity of tumor vessels. However, the nontargeted effect of tTF was weak compared with the coaguligand effect. No mice receiving tTF alone had complete tumor regressions, and only 8% (1 of 12) had-a partial remission. In mice that did not show complete tumor regression after B21-2/10HlO*tTF coaguligand treatment, the tumors grew back from a surviving microscopic rim of cells at the periphery of the tumor. Immunohistochemical examination of these tumors revealed that the vascular endothelium at the invading edge of the tumors lacked detectable class I1 antigens, consistent with a lack of thrombosis of these vessels by the coaguligand, which permitted local tumor cell survival (12). Conceivably, coadministration of a drug acting on the tumor cells themselves might improve efficacy, as we observed with another antivascular therapy (1 3, 14) . We previously demonstrated that a powerfully cytotoxic ricin A-chain immunotoxin directed against the tumor cells themselves was virtually devoid of antitumor activity when administered to mice with large C1300(Muy) tumors (13, 14) . The lack of activitv was a result of the inability of the immunotoxin to gain access to tumor cells in large tumor masses, thus " attesting to the comparative effectiveness of coaguligand therapy.
Our experiments illustrate the therapeutic potential of selective initiation of the blood coagulation cascade in tumor vasculature. For clinical application, this strategy will require the identification of target molecules (antigens, receptors) that are present Table 1 Geographic distribution data for endangered species in the United States were used to locate "hot spots" of threatened biodiversity. The hot spots for different species groups rarely overlap, except where anthropogenic activities reduce natural habitat in centers of endemism. Conserving endangered plant species maximizes the incidental protection of all other species groups. The presence of endangered birds and herptiles, however, provides a more sensitive indication of overall endangered biodiversity within any region. The amount of land that needs to be managed to protect currently endangered and threatened species in the United States is a relatively small proportion of the land mass.
Previous studies have shown that, o n a continental scale, the distributions of wellstudied taxa can act as surrogates or indicators for the distribution of poorly studied taxa (1) (2) (3) (4) . In contrast, studies of the distribution of "hot spots" of diversity for various taxa within the British Isles suggest that there is very little correlation between the distributions of different taxonomic groups (5, 6) . T o date, however, n o such analysis has been done o n a continental or national scale for those species most likely to vanish in the foreseeable future, that is, endangered species. If significant correlations occur in the geographic distributions of different groups of endangered species, it may be possible to use a few well-studied groups as indicators for the purposes of delineating protected areas for other poorly known taxa. T h e extent to which endangered species are concentrated in hot spots of ~o t e n t i a lextinctions and the extent to which hot spots for d~fferent groups overlap mlll influence the strategies we adopt to avert species extinctions and the impact of those strategies o n other human activities (7, 8) . If endangered species are highly concentrated, then fewer areas are likelv to experience conflicts between species protection and other activities. In this study, we used a database of threatened and endangered species in the United States to examine patterns in the geographic distribution of imperiled species (9) . T h e database lists the counties of occurrence of all plants and animals protected under the federal Endangered Species A c t in the 50 states, plus all species, subspecies, and populations proposed for protection under that statute as of August 1995 ( a total of 924 species in 2858 counties). W e grouped the species by state, county, and species group (amphibians, arachnids, birds, clams, 'To whom correspondence should be addressed, E-mail, crLlstacea, fish, insects, lnammals, plants, andy@eno.pr~nceton.edu reptiles, and snails) and then generated dis-SCIENCE VOL 275 24 J.4NUhRY 1997
